34-LB: Effectiveness of Combination Use of a Lifestyle Improvement Support App and a Wearable Device on Glycemic Control in Japanese People with T2DM—STEP-DM

Abstract

Despite the availability of various therapeutic agents for T2DM, about half of patients do not achieve their glycemic control targets in Japan. In recent years, apps and wearable devices supporting diabetes treatment have rapidly spread. However, evidence of their impact, especially in combination, is limited. This is the first study to explore the effectiveness of combination use of a lifestyle improvement support app (TOMOCOTM Mitsubishi Tanabe Pharma Co.) and a wearable device (Fitbit) in Japanese people with T2DM under insufficient glycemic control (jRCT1070220007). Of 61 patients enrolled, 59 completed (HbA1c: 7.57 ± 0.42%, Body weight: 69.12 ± 13.36 kg; at baseline). The participants used TOMOCOTM and Fitbit in addition to conventional diet/exercise and antidiabetic drug therapy for 12 weeks, and were provided feedback/advice based on TOMOCOTM and Fitbit records from health care providers (Fig). At the end of the observation period, HbA1c was significantly decreased (-0.41 ± 0.41%; range -1.9 to 0.7, p<0.001) and body weight was also reduced (-0.88 ± 1.58 kg; range -5.7 to 2.1, p<0.001), and the trend was consistent across the pre-specified patient background. In conclusion, combination use of a lifestyle improvement support app and a wearable device with conventional therapy may be effective for glycemic control in people with T2DM. Disclosure A. Takahashi: Employee; Mitsubishi Tanabe Pharma Corporation. M. Ishii: Employee; Mitsubishi Tanabe Pharma Corporation. Y. Kino: Employee; Mitsubishi Tanabe Pharma Corporation. K. Sasaki: Employee; Mitsubishi Tanabe Pharma Corporation. T. Hashimoto: Employee; Mitsubishi Tanabe Pharma Corporation. T. Matsui: Employee; Mitsubishi Tanabe Pharma Corporation. K. Arakawa: Employee; Mitsubishi Tanabe Pharma Corporation. M. Kunisaki: Research Support; Mitsubishi Tanabe Pharma Corporation, Novo Nordisk.